Schrödinger, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 01, 2023 at 04:00 pm EDT
Share
Schrödinger, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 13.67 million compared to USD 12.31 million a year ago. Revenue was USD 42.57 million compared to USD 36.98 million a year ago. Net loss was USD 62.02 million compared to USD 39.85 million a year ago. Basic loss per share from continuing operations was USD 0.86 compared to USD 0.56 a year ago. Diluted loss per share from continuing operations was USD 0.86 compared to USD 0.56 a year ago.
For the nine months, sales was USD 52.07 million compared to USD 36.35 million a year ago. Revenue was USD 142.54 million compared to USD 124.11 million a year ago. Net income was USD 71.39 million compared to net loss of USD 121.98 million a year ago. Basic earnings per share from continuing operations was USD 1 compared to basic loss per share from continuing operations of USD 1.71 a year ago. Diluted earnings per share from continuing operations was USD 0.95 compared to diluted loss per share from continuing operations of USD 1.71 a year ago.
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.
SCHRÖDINGER, INC. 
